![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
M Rinaldi-Carmona, C Congy, V Santucci, J Simiand, B Gautret, G Neliat, B Labeeuw, G Le Fur, P Soubrie and JC Breliere
Sanofi Recherche, Montpellier, France.
A new potent, selective and p.o. active serotonergic [5- hydroxytryptamine (5-HT2)] receptor antagonist, SR 46349B [trans, 4- ([3Z)3-(2-dimethylaminoethyl)oxyimino-3(2-flurophenyl++ +)propen-1- yl]phenol hemifumarate) has been characterized by a series of "in vitro" and "in vivo" methods. Based upon binding studies with 5-HT2 receptors in rat brain cortical membranes and blockade of 5-HT-induced contractions in isolated tissues (rabbit thoracic aorta, rat jugular vein, rat caudal artery, rat uterus and guinea pig trachea), SR 46349B showed high affinity for 5-HT2 receptors. Furthermore, SR 46349B displayed moderate affinity for the 5-HT1C receptor and had no affinity for the other 5-HT1 subclass (5-HT1A, 5-HT1B or 5-HT1D), dopamine (D1 or D2), "alpha" adrenergic (alpha-1 or alpha-2), sodium and calcium channel and histamine (H1) receptors. It did not interact with histamine (H1), alpha-1 adrenergic and 5-HT3 receptors in smooth muscle preparations. No inhibition of the uptake of norepinephrine, dopamine or 5-HT was seen. Based upon blockade of pressor responses to 5-HT in pithed rats and in vivo binding studies in mice, SR 46349B was found to be a potent and p.o. active 5-HT2 receptor antagonist with a relatively long duration of action. Behavioral experiments, including mescaline- and 5-hydroxytryptophan-induced head twitches and learned helplessness, as well as sleep-waking cycle and EEG spectral parameter studies, indicated that SR 46349B has a classical 5-HT2 psychopharmacological antagonist profile.
This article has been cited by other articles:
|
|
 |
|
  J. A. Lieberman, F. P. Bymaster, H. Y. Meltzer, A. Y. Deutch, G. E. Duncan, C. E. Marx, J. R. Aprille, D. S. Dwyer, X.-M. Li, S. P. Mahadik, et al. Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection Pharmacol. Rev., September 1, 2008; 60(3): 358 - 403. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. E. Vanover, D. M. Weiner, M. Makhay, I. Veinbergs, L. R. Gardell, J. Lameh, A. L. Del Tredici, F. Piu, H. H. Schiffer, T. R. Ott, et al. Pharmacological and Behavioral Profile of N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) Carbamide (2R,3R)-Dihydroxybutanedioate (2:1) (ACP-103), a Novel 5-Hydroxytryptamine2A Receptor Inverse Agonist J. Pharmacol. Exp. Ther., May 1, 2006; 317(2): 910 - 918. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Ootsuka and W. W. Blessing Activation of slowly conducting medullary raphe-spinal neurons, including serotonergic neurons, increases cutaneous sympathetic vasomotor discharge in rabbit Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2005; 288(4): R909 - R918. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Filip, M. J. Bubar, and K. A. Cunningham Contribution of Serotonin (5-Hydroxytryptamine; 5-HT) 5-HT2 Receptor Subtypes to the Hyperlocomotor Effects of Cocaine: Acute and Chronic Pharmacological Analyses J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 1246 - 1254. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Y. Meltzer, L. Arvanitis, D. Bauer, W. Rein, and Meta-Trial Study Group Placebo-Controlled Evaluation of Four Novel Compounds for the Treatment of Schizophrenia and Schizoaffective Disorder Am J Psychiatry, June 1, 2004; 161(6): 975 - 984. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Meyer, S. McMain, S. H. Kennedy, L. Korman, G. M. Brown, J. N. DaSilva, A. A. Wilson, T. Blak, R. Eynan-Harvey, V. S. Goulding, et al. Dysfunctional Attitudes and 5-HT2 Receptors During Depression and Self-Harm Am J Psychiatry, January 1, 2003; 160(1): 90 - 99. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. J. Aloyo, K. D. Dave, T. Rahman, and J. A. Harvey Selective and Divergent Regulation of Cortical 5-HT2A Receptors in Rabbit J. Pharmacol. Exp. Ther., December 1, 2001; 299(3): 1066 - 1072. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Millan, R. Schreiber, S. Monneyron, B. Denorme, C. Melon, S. Queriaux, and A. Dekeyne S-16924, a Novel, Potential Antipsychotic with Marked Serotonin1A Agonist Properties. IV. A Drug Discrimination Comparison with Clozapine J. Pharmacol. Exp. Ther., April 1, 1999; 289(1): 427 - 436. [Abstract] [Full Text]
|
|
|
|
 |
|
 E. J. Pappert, C. G. Goetz, T. Q. Vu, Z. D. Ling, S. Leurgans, R. Raman, and P. M. Carvey Animal model of posthypoxic myoclonus: Effects of serotonergic antagonists Neurology, January 1, 1999; 52(1): 16 - 16. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
